D
espite advances in noninvasive assessment of hepatic diseases, parenchymal liver biopsy remains indispensable for diagnosis and management. Although endoscopic ultrasound (EUS)-guided fineneedle aspiration (FNA) is accepted for obtaining histology of focal liver lesions, EUS-guided biopsy for parenchymal disease has recently emerged because flexible, dedicated, large-bore core needles have been introduced. 1 One such novel fork-tip core needle demonstrated improved histologic yield with a lower number of passes as compared with FNA needles for non-liver lesions. 2 We sought to demonstrate that EUSguided core liver parenchymal biopsy by using a largediameter fork-tip needle can produce adequate samples to establish diagnoses and to compare our results with available literature.
Methods
A single institution, retrospective review was made of prospectively identified patients with abnormal liver function tests (LFTs) who underwent diagnostic EUS for pancreaticobiliary indications. If no definitive evidence of biliary obstruction was present or in cases of suspected or known primary sclerosing cholangitis (PSC), biopsies were obtained from the left lobe of the liver by one gastroenterologist via transgastric approach by using a 19-gauge core biopsy needle (SharkCore; Medtronic, Sunnyvale, CA). A "slow-pull" technique was used where the needle was rapidly advanced into the parenchyma and then slowly withdrawn at the same rate as the stylet. This process was repeated until the stylet was almost out of the needle, resulting in several needle actuations and considered as one pass. Tissue was placed into formalin and sent to surgical pathology. For this study all specimens were retrospectively and independently reviewed by one experienced liver pathologist only to quantitate total specimen length (TSL) and number of complete portal triads (CPTs). Parameters for adequacy of samples were defined as number of CPTs 11 and TSL 30 mm, as per American Association for the Study of Liver Diseases (AASLD) guidelines. 3 For comparative purposes a comprehensive literature search was performed to identify fully published studies in which a 19-gauge needle was used for EUS-guided parenchymal liver biopsy.
Results
A total of 24 consecutive patients were included (Table 1 ). Median number of passes was 2 (range, 1-3). Median TSL was 65.6 mm (range, 17-167.4), and median CPT was 32.5 (range, 5-85). Histologic diagnosis was achieved in 24 of 25 cases (96%). Most common diagnoses included nonalcoholic steatohepatitis (42%), PSC (21%), cirrhosis (13%), and congestion from heart failure (8%). Adequacy of samples based on AASLD criteria for CPT and TSL was 95.8% and 87.5%, respectively. Outpatients were not routinely admitted. Of 2 patients admitted for pain, one experienced a serious adverse event (4%, subcapsular bleeding) and was managed conservatively.
Discussion
EUS-guided liver biopsy by using a new dedicated 19-gauge core needle is safe and provides excellent diagnostic yield with a minimal number of passes. By using EUS guidance, liver biopsy for parenchymal disease can provide advantages over traditional methods for liver biopsy. EUS-guided biopsies have been shown to be non-inferior to those obtained by percutaneous and transjugular routes. 4 Patient cooperation is not required, and needle passage is monitored real-time with Doppler assistance to avoid vascular structures, which may reduce hemorrhage. It can also be performed at the same time for patients undergoing EUS for evaluation of biliary disorders or abnormal LFTs. Current literature on EUSguided liver biopsy is summarized in Table 2 , including first-generation core needles not currently used and FNA needles not designed to obtain core tissue. Despite variability in these studies, specimen quality appears to be adequate on the basis of AASLD guidelines for CPT and TSL, with definitive diagnoses achieved in 90%-100% of patients. On the basis of our cohort, specimen adequacy far exceeds that of current standards, which may be due to the use of a dedicated fork-tip needle, which was recently shown to be superior to EUS FNA needles and two 18-gauge percutaneous biopsy needles in human cadaveric tissue. 5 Standards for specimen adequacy using EUS have not been established but should mirror those used for percutaneous biopsy. Length of specimen, number of CPTs, and needle-gauge type are important factors in diagnostic yield. 5 Questions remain regarding EUS-guided liver biopsy including type of needle and techniques used (eg, the use and amount of suction), sampling either left or right lobes (performed transduodenally), and minimum number of passes required to achieve adequacy. Additional evidence is needed regarding EUS-guided liver biopsy in patients with cirrhosis, ascites, PSC, and after liver transplantation. Nevertheless, we believe EUS-guided liver biopsy is useful for clinicians in the evaluation of patients with liver disease and can be safely performed at the time of diagnostic EUS exam in the evaluation of biliary disease or abnormal LFTs.
